导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.48% | 1380/4773 |
| 近一周 | -2.50% | 2378/5462 |
| 近一月 | -4.86% | 2820/5421 |
| 近一季 | -8.36% | 2788/5209 |
| 近半年 | -5.81% | 2957/4920 |
| 近一年 | 8.62% | 1172/4366 |
| 近两年 | 72.01% | 940/2954 |
| 近三年 | 37.84% | 778/2253 |
| 成立以来 | 62.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.07% 1072/4961 |
18.62% 1361/5312 |
- - |
- - |
| 2025 | 31.04% 1268/4813 |
2.18% 1446/3635 |
1.88% 2051/4076 |
24.42% 1470/4524 |
1.18% 1484/4813 |
| 2024 | 6.60% 1742/3463 |
-2.59% 1385/2808 |
-5.16% 1661/3014 |
15.94% 1587/3129 |
-0.47% 1432/3463 |
| 2023 | -5.63% 758/2656 |
7.63% 546/2280 |
-3.97% 986/2385 |
-4.45% 1143/2515 |
-4.44% 1037/2655 |
| 2022 | -17.65% 616/2207 |
-13.35% 741/1919 |
3.22% 1190/2016 |
-10.31% 379/2113 |
2.66% 867/2208 |
| 2021 | 17.41% 232/1822 |
-1.32% 467/1255 |
9.68% 534/1330 |
4.94% 308/1466 |
3.38% 444/1822 |
| 2020 | 24.82% 628/1250 |
-4.06% 338/1028 |
16.75% 417/1067 |
7.61% 769/1164 |
3.55% 906/1184 |
| 2019 | 26.74% 569/1092 |
30.99% 218/739 |
-9.81% 693/788 |
1.00% 437/850 |
6.22% 640/918 |
| 2018 | - - |
- - |
- - |
-7.12% 434/660 |
-11.48% 299/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证500ETF联接C VS. 长安沪深300非周期A(740101) |